Attana Application Note: Crude samples analysis - Screening and characterization of hybridoma supernatants

Document -

Attana Application Note: Crude samples analysis - Screening and characterization of hybridoma supernatants

The objective of this application note was primarily to screen mouse IgG antibodies from crude samples for dissociation rates of bound antigen, and to determine detailed kinetic rate constants between the antigen and an antibody selected in the screen. Among other things, a method to capture mouse IgG from hybridoma supernatants was developed which can be replicated for capture of human IgGs.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download

Topics

  • Medical research

Categories

  • label free
  • antibodies
  • crude samples
  • biosensor

Related content

  • Attana launches new biosensor surface

    Crude samples, such as supernatants or hybridomas, are often time consuming and expensive to analyse. This is one of the reasons Attana has developed a new low non-specific binding carboxyl surface, the LNB carboxyl.

  • Attana's core business!

    View article in Innovations in Pharmaceutical Technology (IPT), a brief overview of Attana's core business. http://www.iptonline.com/viewinn.asp?cat=2&article=285

  • Attana Launches New Reagents

    Attana today announced the launch of a series of four commercial reagents and kits to address customers' needs for high usability and quality research.

  • Biotech companies - Ways to work more efficiently

    Ernst & Young recently released their 24th annual report Beyond borders: global biotechnology report 2010, presenting, among other things, five guiding principles for biotech companies working in the new economy where funding is scarce and customers careful: